NSE filing, NSE: STAR. Summary written from the filing by ALFA Finder's alert engine.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,037.30
- Market cap
- ₹9,562 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 15.5×Sector 47.2×
- Promoter holding
- 29.00%+1.09% QoQ
- FII holding
- 27.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Earnings Call Transcript: Key Takeaways
Record Q2 revenue ₹1,430 Cr (+17% YoY), Ex-US overtakes US, but EBITDA margin fell to 17.6% on input costs; US aspiration slips beyond FY28.
Strides Pharma Science Management Change
Strides Pharma's board appointed Biren Gabhawala as Non-Executive Independent Director effective November 1, 2026, for five years. He is a Chartered Accountant with extensive audit and listed-company board experience.
- Execution
- Five-year term effective November 1, 2026
Strides Pharma Science Employee Stock Options
Strides Pharma allotted 7,500 equity shares to an employee exercising options under the Strides ESOP 2016 Plan. Paid-up capital rises to 92,180,214 shares.
Strides Pharma Science Investor Presentation: Key Takeaways
Q2FY27 revenue ₹14,297m (+17.1% YoY), EBITDA ₹2,509m (17.6% margin), reported PAT ₹1,341m (+2.0%). Ex-US revenue surpassed US for the first time; US ~$375m FY28 aspiration pushed beyond FY28.
Strides Pharma Science Results Update
Strides Pharma reported Q2FY27 revenue of ₹14,297m, up 17.1% YoY, and EBITDA of ₹2,509m, up 8.4%, in a press release. Reported PAT rose 2.0% to ₹1,341m.
Strides Pharma Science Q2 FY27 Results: Net Profit ₹134.1 Cr, Up 2.0% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,430 Cr (+17.1% YoY) and net profit of ₹134.1 Cr (+2.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹134.1 Cr · +2.0% YoY
Other dividend announcements
All →Metropolis Healthcare Dividend
Metropolis Healthcare declared an interim dividend of ₹1 per equity share for FY 26-27. The record date is 9 November 2026.
Bayer Cropscience Dividend
Bayer CropScience declared an interim dividend of Rs. 90 per equity share for FY 2026-27 on November 3, 2026. Record date is November 12, 2026 and payment is due November 30, 2026.
Amrutanjan Health Care Dividend
Amrutanjan Health Care set November 7, 2026 as the record date for its first FY2026-27 interim dividend. The dividend amount per share is not stated.
BMW Ventures Dividend
BMW Ventures declared an interim dividend of Rs 1.5 per equity share for 2026-27. Record date is 13 November 2026, with payment by 2 December 2026.
Remus Pharmaceuticals Dividend
Remus Pharmaceuticals has fixed 7 November 2026 as the record date for its 1st interim dividend for FY 2026-27, declared at today's board meeting. The filing does not state the per-share dividend amount.
Mobavenue AI Tech Dividend
Mobavenue AI Tech Ltd has declared an interim dividend of ₹0.10 per equity share for FY 2026-27. The company fixed November 13, 2026, as the record date for payment.